Background Coronavirus disease 2019 (COVID-19) causes thromboembolic complications during or post-infection period despite a lack of conventional risk factors. The study aims to learn fundamental changes in COVID-19 patients who underwent embolectomy in terms of clinical characteristics and clot composition. Methods In a retrospective cohort study design, we evaluated 21 patients who underwent embolectomy in our clinic between March 12, 2020, and December 31, 2020. Demographics, characteristics, and laboratory values were abstracted and analyzed. Histopathological assessment was held in the pathology department. Results Of these 21 patients, 11 (52.3%) were SARS-CoV-2 positive and 10 (47.6%) were SARS-CoV-2 negative. There is no statistical difference in terms of anatomic distribution, diagnostic method, length of hospital stay, amputation or mortality levels. Thromboembolic material of COVID-19 patients include significantly less red blood cell (RBC) (21.2–32.6%; P = 0.01), more lymphocyte (14.1–2.6%; P < 0.001), and more leukocyte (27.1–22.1%; P = 0.05). There was no statistical difference between the fibrin ratio. Conclusions Inflammatory cells are prominent in arterial thromboembolic material of COVID-19 patients. A combination of hyperinflammation and prothrombotic status may be responsible for this phenomenon.

Epithelioid hemangioendothelioma is a rare malignant vascular tumor which originates from the vascular endothelial or dendritic cells and has a moderate malignancy between benign hemangioma and malignant hemangiosarcoma, arising from vascular structures. Radical resection of epithelioid hemangioendothelioma is recommended, due to both its malignant nature and the adverse effects of associated complications on mortality and morbidity. In this article, we present a rare case of primary cardiac epithelioid hemangioendothelioma accompanied by a left atrial myxoma which was treated by resection.